安杰思收盘上涨4.67%，滚动市盈率18.51倍，总市值54.95亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Anjiasi, a company in the medical device industry, which has a current PE ratio of 18.51, significantly lower than the industry average of 51.70 [1][2] - Anjiasi's total market capitalization is reported at 5.495 billion yuan, ranking 41st in the medical device sector based on PE ratio [1][2] - As of the first quarter of 2025, 11 institutions hold shares in Anjiasi, with a total of 17.7325 million shares valued at 1.26 billion yuan [1] Group 2 - Anjiasi specializes in the research, production, and sales of minimally invasive diagnostic and therapeutic instruments, with key products including GI, EMR/ESD, and ERCP diagnostic series [1] - The company achieved significant government honors, including recognition as a "Zhejiang Provincial Enterprise Technology Center" and "Zhejiang Provincial High-Growth Biopharmaceutical Enterprise" [1] - In the latest financial report for the first quarter of 2025, Anjiasi reported revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.2483 million yuan, reflecting a 6.57% increase [1]